CV

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

Retrieved on: 
Thursday, June 15, 2023

“We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.

Key Points: 
  • “We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.
  • The beneficial effect of bempedoic acid on MVE reduction generally improved over time, similar to what was observed in statin CVOTs.
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Queensberry Mining and Development Corp. Acquires Additional Shares of St. Augustine Gold and Copper Limited

Retrieved on: 
Thursday, June 15, 2023

Queensberry acquired 91,778,683 Shares representing approximately 9.98% of the issued and outstanding Shares (on a non-diluted basis).

Key Points: 
  • Queensberry acquired 91,778,683 Shares representing approximately 9.98% of the issued and outstanding Shares (on a non-diluted basis).
  • Immediately prior to the Private Placement, Queensberry owned 408,678,556 Shares (approximately 44.44% of the issued and outstanding Shares).
  • As a result of the Private Placement, Queensberry has increased in ownership of Shares by 5.04% and now owns 500,457,239 Shares (approximately 49.48% of the issued and outstanding Shares).
  • Queensberry’s President and CEO, Manuel Paolo A. Villar, personally has ownership and control over an additional 218,500 Shares (approximately 0.02% of the issued and outstanding Shares).

Aware Unveils Aware IQ, the AI-Powered Contextual Intelligence Platform

Retrieved on: 
Wednesday, June 14, 2023

COLUMBUS, Ohio, June 14, 2023 /PRNewswire/ -- Today, Aware announced the launch of Aware IQ, an artificial intelligence data platform, purpose-built to understand the unique human context of workplace conversations at scale. Customers using Aware IQ and its portfolio of applications gain real-time visibility into every aspect of their business, including the risks and opportunities that they were previously unaware of.

Key Points: 
  • COLUMBUS, Ohio, June 14, 2023 /PRNewswire/ -- Today, Aware announced the launch of Aware IQ, an artificial intelligence data platform, purpose-built to understand the unique human context of workplace conversations at scale.
  • Aware customers unlock insights from that collaboration data to understand employee needs, which have often been ignored, misunderstood, or only partially captured through ineffective, outdated surveys.
  • Aware IQ's groundbreaking interpretive natural language processing (NLP) and computer vision (CV) models enable companies to utilize secure, personalized predictive, and generative AI models.
  • "Today, we're proud to say that Aware is used by the world's most innovative brands to power the employee experience, validating our investment and approach to artificial intelligence.

NTT Research and NCVC to Form Bio Digital Twin Center

Retrieved on: 
Thursday, June 8, 2023

NTT Research, Inc. , (NTTR) a division of NTT (TYO:9432), and the National Cerebral and Cardiovascular Center (NCVC) today announced an agreement to jointly launch a Bio Digital Twin Center in Suita, Japan.

Key Points: 
  • NTT Research, Inc. , (NTTR) a division of NTT (TYO:9432), and the National Cerebral and Cardiovascular Center (NCVC) today announced an agreement to jointly launch a Bio Digital Twin Center in Suita, Japan.
  • This initiative extends and expands the scope of a joint agreement on cardiovascular bio digital twin (CV BioDT) research between the two organizations reached in 2020.
  • Scientists at the NTTR-NCVC Bio Digital Twin Center intend to create applications by integrating mathematical models, co-developed by the MEI Lab and NCVC, onto the CV BioDT platform advanced by the MEI Lab.
  • Kazunori Uemura and Keita Saku (M.D., Ph.D.s) will lead the NTTR-NCVC Bio Digital Twin Center, respectively, as laboratory chief and acting director.

Your LinkedIn doesn't need to be perfect – four ways to build an authentic profile to boost your personal brand

Retrieved on: 
Friday, June 2, 2023

But if you’ve spent any time on LinkedIn, you’ll know it’s something anyone can develop with well-crafted posts and engagement.

Key Points: 
  • But if you’ve spent any time on LinkedIn, you’ll know it’s something anyone can develop with well-crafted posts and engagement.
  • In recent years, students and young professionals have turned personal branding into a tool for success in competitive, global job markets.
  • A personal brand is about both how you differentiate yourself from others, and about how others perceive you.
  • We also spoke with recruiters and a career advisor about creating personal brands on LinkedIn.

1. Stay up to date

    • They use these profiles to evaluate potential hires’ talents and professional skills, but also their fit with company culture.
    • The more current and detailed your profile is, the easier it will be for the right employer to find you.

2. Don’t leave out your weaknesses

    • But our interviews reveal that taking the risk to showcase your weaknesses and imperfections can pay off.
    • Participants told us that these posts are popular with followers, help generate conversations, and result in stronger personal brands.
    • The post attracted hundreds of likes and comments, including advice, encouragement and similar stories from people in her network.

3. Engage with others

    • You should initiate conversations, collect thoughts and gather feedback from others in your field.
    • As one student told us:
      We’re all developing, and I don’t want to show employers a perfect, yet not ‘me’ image.
    • We’re all developing, and I don’t want to show employers a perfect, yet not ‘me’ image.

4. Keep your personal life separate

    • It is important to set clear boundaries between your work and private life, and make good use of privacy settings to maintain your personal brand.
    • Your posts on professional sites can be personal, but from a professional context and not something you don’t want recruiters to see – for example, photos that show you partying.

Metcal Introduces CV-IOT Gateway Module and Desktop Application

Retrieved on: 
Wednesday, May 31, 2023

By connecting the CV-IOT gateway to a Metcal Connection Validation™ (CV) soldering system and a computer or network, operations can utilize information on every joint to improve process control and efficiency in the soldering process.

Key Points: 
  • By connecting the CV-IOT gateway to a Metcal Connection Validation™ (CV) soldering system and a computer or network, operations can utilize information on every joint to improve process control and efficiency in the soldering process.
  • A standard handheld barcode scanner can easily be added to the setup for board-level traceability.
  • "CV-IOT makes real-time process control and traceability simple," said Seerena Wright, Metcal Product Manager.
  • To ensure data security, the CV-IOT module plugs directly into the CV unit and the computer or network through a wired connection.

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

Retrieved on: 
Monday, May 22, 2023

“We are focused on advancing treatment options for chronic, debilitating immune-mediated diseases such as RA and are excited to present further analyses on filgotinib’s efficacy and safety profile at this year’s EULAR congress,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, Immunology, at Galapagos.

Key Points: 
  • “We are focused on advancing treatment options for chronic, debilitating immune-mediated diseases such as RA and are excited to present further analyses on filgotinib’s efficacy and safety profile at this year’s EULAR congress,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, Immunology, at Galapagos.
  • “Our presence at EULAR underscores our firm commitment to develop transformational therapies to improve the lives of patients around the world.”
    A number of abstracts will present trial data analyses on filgotinib, a once-daily oral preferential JAK-1 inhibitor, for the treatment of moderate to severe active RA.
  • Furthermore, Galapagos is hosting a symposium: “JAK to reality: seeking clarity in RA”, which will focus on key considerations when selecting treatments for RA patients, efficacy and safety of JAK inhibitors, and the practical use of JAK inhibitors in the treatment of RA patients.
  • Distinct treatment responses in patients with rheumatoid arthritis receiving filgotinib 200 mg over 12 months: A post hoc analysis of FINCH 1
    What trade-offs are acceptable to rheumatoid arthritis patients during treatment selection?

Bempedoic acid significantly reduces the risk of major adverse cardiovascular events, and increased combination therapies can help more patients achieve LDL-C goals — late breaking EAS data

Retrieved on: 
Tuesday, May 23, 2023

Both studies were presented in a late-breaker session at the 91st European Atherosclerosis Society congress.

Key Points: 
  • Both studies were presented in a late-breaker session at the 91st European Atherosclerosis Society congress.
  • Nearly 80% of patients who are at high- or very high-risk of CV events in Europe do not attain the guideline-recommended LDL-C goals, putting them at high risk of suffering an acute and often life-threatening cardiovascular event.
  • The CLEAR Outcomes trial answers those remaining questions and shows that bempedoic acid reduces the risk of major cardiovascular events in patients at high- and very high-risk.
  • We now know that, as an additional treatment option, bempedoic acid can not only help patients reach their guideline LDL-C recommendations but also lower their CV risk.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.

New urban health 'accelerator' aims to transform cardiovascular population health globally

Retrieved on: 
Monday, May 22, 2023

The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.

Key Points: 
  • The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.
  • Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world's leading cause of death, according to the World Health Organization (WHO)1.
  • The accelerator aims to replicate CARDIO4Cities, the cardiovascular (CV) population health approach pioneered and validated by the Novartis Foundation, in 30 major cities within the next three years.
  • As a neutral broker between city governments, health experts, industry, implementing partners, funders and investors, the accelerator pledges the global community to direct action and funding toward transforming CV population health and equity.